^
Association details:
Biomarker:MDM4 mutation
Cancer:Non Small Cell Lung Cancer
Drug Class:Immunotherapy
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors.

Published date:
05/19/2021
Excerpt:
Pts with NSCLC treated with ICIs...98 of 427 pts (23%)had HP and an additional 86 pts (20%) had progressive disease...By tumor gene alterations, HP was seen in pts with: EGFR (20/60), STK11/LKB1 (16/25); and MDM2/4 (4/7).
DOI:
10.1200/JCO.2021.39.15_suppl.9105